GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guangdong Hybribio Biotech Co Ltd (SZSE:300639) » Definitions » ROIC %

Guangdong Hybribio Biotech Co (SZSE:300639) ROIC % : -3.20% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Guangdong Hybribio Biotech Co ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Guangdong Hybribio Biotech Co's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2024 was -3.20%.

As of today (2024-05-22), Guangdong Hybribio Biotech Co's WACC % is 8.29%. Guangdong Hybribio Biotech Co's ROIC % is -0.13% (calculated using TTM income statement data). Guangdong Hybribio Biotech Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Guangdong Hybribio Biotech Co ROIC % Historical Data

The historical data trend for Guangdong Hybribio Biotech Co's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guangdong Hybribio Biotech Co ROIC % Chart

Guangdong Hybribio Biotech Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.25 34.40 46.94 70.92 0.44

Guangdong Hybribio Biotech Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.77 5.25 -426.10 -4.10 -3.20

Competitive Comparison of Guangdong Hybribio Biotech Co's ROIC %

For the Diagnostics & Research subindustry, Guangdong Hybribio Biotech Co's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guangdong Hybribio Biotech Co's ROIC % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guangdong Hybribio Biotech Co's ROIC % distribution charts can be found below:

* The bar in red indicates where Guangdong Hybribio Biotech Co's ROIC % falls into.



Guangdong Hybribio Biotech Co ROIC % Calculation

Guangdong Hybribio Biotech Co's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=9.784 * ( 1 - -86.1% )/( (4098.993 + 4166.476)/ 2 )
=18.208024/4132.7345
=0.44 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6741.177 - 1230.352 - ( 1411.832 - max(0, 1362.832 - 4400.278+1411.832))
=4098.993

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5725.791 - 487.328 - ( 1071.987 - max(0, 507.916 - 3176.925+1071.987))
=4166.476

Guangdong Hybribio Biotech Co's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2024 is calculated as:

ROIC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-162.38 * ( 1 - 17.02% )/( (4166.476 + 4257.583)/ 2 )
=-134.742924/4212.0295
=-3.20 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5725.791 - 487.328 - ( 1071.987 - max(0, 507.916 - 3176.925+1071.987))
=4166.476

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5528.464 - 350.584 - ( 920.297 - max(0, 367.081 - 2977.277+920.297))
=4257.583

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guangdong Hybribio Biotech Co  (SZSE:300639) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Guangdong Hybribio Biotech Co's WACC % is 8.29%. Guangdong Hybribio Biotech Co's ROIC % is -0.13% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Guangdong Hybribio Biotech Co ROIC % Related Terms

Thank you for viewing the detailed overview of Guangdong Hybribio Biotech Co's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Guangdong Hybribio Biotech Co (SZSE:300639) Business Description

Traded in Other Exchanges
N/A
Address
D 5-3-3-4, North High-tech Zone, Economic Development Zone, Chaozhou City, CHN, 521000
Guangdong Hybribio Biotech Co Ltd is a Chinese company engaged in offering vitro diagnostic assays. Its products include in-vitro diagnostic kits, female sample collection kit, DNA extraction kit, and other devices. The company's products help in the infectious pathogens detection and genetic disease detection, including human papillomavirus, thalassemia, G6PD, hearing loss susceptibility, phenylketonuria, and early cancer detection, among others. The company has a business presence in China and various other countries.

Guangdong Hybribio Biotech Co (SZSE:300639) Headlines

No Headlines